Article Details
Retrieved on: 2022-11-24 17:13:32
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Xeris Biopharma and Horizon Therapeutics signed a partnership and option agreement to develop a subcutaneous injection of teprotumumab.
Article found on: www.pharmaceutical-technology.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here